Upcoming Events

Images from the 2014 JMML International Symposium in San Francisco, CA, December 2014 and the 7th International Symposium on JMML, Myelodysplastic Syndromes and Bone Marrow Failure in Aarhus, Denmark, October 2015

Welcome!

Juvenile Myelomonocytic Leukemia (JMML) is a rare form of leukemia which affects young children, generally under the age of five.

The JMML Foundation exists to find a cure for JMML, and to improve the quality of life of JMML patients and families through research, education, advocacy, and charity.


                                                           

New Clinical Trial for JMML

Posted January 5, 2018

A trial sponsored by the Children’s Oncology Group is now open at various children’s hospitals across the United States. This trial called ADVL1521 is specifically designed for children with juvenile myelomonocytic leukemia (JMML) who have not responded to regular treatments (either intravenous chemotherapy or stem cell transplantation). ADVL1521 will be using an oral medication called trametinib that will be given once daily and has been shown to be effective in other Ras driven cancers. If you know a child who could benefit from learning about this trial, please feel free to reach out to your local pediatric oncologist or to Dr. Elliot Stieglitz at the University of California San Francisco who is overseeing this clinical trial.  

Contact information and more details about the clinical trial can be found on ClinicalTrials.gov: https://clinicaltrials.gov/ct2/show/NCT03190915.

The JMML Research Roadmap was revised during the 2015 JMML International Symposium.  Three questions have been answered, and others have come to light since our last update.

Click here to see the progress made towards a cure since 2011.


This website is certified by Health On the Net Foundation. Click to verify.This site complies with the HONcode
standard for trustworthy health
 
information:  verify here.



Copyright (c) 2016 The JMML Foundation
Powered by Wild Apricot Membership Software